Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Antibodies to watch in 2019.MAbs. 2019; 11: 219-238
- Antibodies to watch in 2022.MAbs. 2022; 14: 2014296
- The pharmacology and therapeutic applications of monoclonal antibodies.Pharmacol Res Perspect. 2019; 7: e00535
- Protein therapeutics: a summary and pharmacological classification.Nat Rev Drug Discov. 2008; 7: 21-39
- Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.Arch Biochem Biophys. 2012; 526: 146-153
- Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience.Adv Ther. 2017; 34: 2232-2273
- Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.Leuk Lymphoma. 2016; 57: 1021-1032
Mocquot P., Mossazadeh Y., Lapierre L., et al., The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials, J Clin Pharm Ther, 47 (9), 2022, 1337-1351.
- The basic principles of chimeric antigen receptor design.Cancer Discov. 2013; 3: 388-398
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.Nat Commun. 2016; 7: 12320
- CAR T cell immunotherapy for human cancer.Science. 2018; 359: 1361-1365
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.Blood. 2015; 125: 4017-4023
- CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).Ther Adv Hematol. 2015; 6: 228-241
- CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences.Front Oncol. 2020; 10: 849
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2021; 22: 1403-1415
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014; 371: 1507-1517
- Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.J Clin Oncol. 2015; 33: 540-549
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med. 2018; 24: 20-28
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood. 2016; 128: 1688-1700
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385: 517-528
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood. 2017; 129: 3322-3331
- Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy.Cancer Discov. 2015; 5: 1282-1295
- Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.J Transl Med. 2017; 15: 59
- Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Haematologica. 2017; 102: e368-e370
- VS38 identifies myeloma cells with dim CD38 expression and plasma cells following daratumumab therapy, which interferes with CD38 detection for 4 to 6 months.Am J Clin Pathol. 2020; 153: 221-228
- The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.Br J Haematol. 1998; 100: 637-646
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia. 2017; 31: 2094-2103
- VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.Int J Hematol. 2019; 110: 322-330
- VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma.Am J Clin Pathol. 2022; 157: 494-497
- Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Cytometry B Clin Cytom. 2016; 90: 81-90
- Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med. 2018; 378: 449-459
- A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.Cytometry B Clin Cytom. 2018; 94: 112-120
- Flow Cytometric monitoring for residual disease in B lymphoblastic leukemia post T cell engaging targeted therapies.Curr Protoc Cytom. 2018; 86: e44
- Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.Br J Haematol. 2022; 197: 76-81
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.Leukemia. 2019; 33: 2854-2866
- Antigen expression patterns reflecting genotype of acute leukemias.Leukemia. 2002; 16: 1233-1258
- CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.J Immunother. 2017; 40: 187-195
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.Blood. 2017; 129: 100-104
- Mechanisms of resistance to CAR T cell therapy.Nat Rev Clin Oncol. 2019; 16: 372-385
Kurzer J.H. and Weinberg O.K., To B- or not to B-: a review of lineage switched acute leukemia, Int J Lab Hematol, 44 Suppl 1, 2022, 64-70.
Lamble A., Myers R.M., Taraseviciute A., et al., Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells, Blood Adv, 7 (4),2022, 575-585.
- DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.Haematologica. 2021; 106: 2066-2075
- Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.Pediatr Blood Cancer. 2018; 65: e27265
- Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.Leukemia. 2021; 35: 3272-3277
- Antigen loss after targeted immunotherapy in hematological malignancies.Clin Lab Med. 2021; 41: 341-357
- Cytokine release syndrome: current perspectives.ImmunoTargets Ther. 2019; 8: 43-52
- Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line.Leuk Res. 1992; 16: 751-760
- Artifactual kappa light chain restriction of marrow hematogones: a potential diagnostic pitfall in minimal residual disease assessment of plasma cell myeloma patients on daratumumab.Cytometry B Clin Cytom. 2020; 98: 68-74
- False-positive light chain clonal restriction by flow cytometry in patients treated with alemtuzumab: potential pitfalls for the misdiagnosis of B-cell neoplasms.Am J Clin Pathol. 2019; 151: 154-163
- Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.Leuk Lymphoma. 2018; 59: 978-982
Article info
Publication history
Published online: March 08, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
